Market Intelligence, Clinical Progress, and High-Purity Reagents for Central Nervous System and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HTR2C drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | HTR2C Lentivirus Premade Particles (Full-length human ORF, CMV promoter, Puro resistance). For stable cell line generation & Calcium Flux assays. Sequence Verified. | View HTR2C Products |
| Stable Cell Line | HTR2C Overexpressing HEK293 (Pre-established stable pool, >95% expression efficiency validated by Flow Cytometry). | View HTR2C Products |
| Antigen (Control) | HTR2C Membrane Protein Fraction (HEK293-derived, high purity >85%). Suitable for binding assays. | View HTR2C Products |
| Benchmark Ab | Anti-HTR2C Reference mAb (Recombinant rabbit monoclonal, validated for Flow Cytometry). | View HTR2C Products |
| Validator | HTR2C siRNA Set (Gene-specific knockdown validated at mRNA level; includes scrambled negative control). | View HTR2C Products |
| Related Target: HTR2A | 5-HT2A Receptor. Required for selectivity profiling vs. antipsychotic side effects. | View HTR2A Products |
| Related Target: HTR2B | 5-HT2B Receptor. Critical safety counter-screen (valvular heart disease liability). | View HTR2B Products |
| Related Target: MC4R | Melanocortin-4 Receptor. Downstream appetite regulation pathway synergy for obesity combination studies. | View MC4R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex GPCR Conformation & Glycosylation | HEK293 Expression System preserves native post-translational modifications; Lentiviral integration ensures stable, high-density receptor surface expression for physiological relevance. |
| Subfamily Counter Screening (HTR2A/2B) | Parallel Lentivirus for HTR2A and HTR2B available with matched genetic backgrounds for rigorous off-target liability assessment. |
| Bias Signaling (Gq vs Arrestin) | High-titer Lentivirus (TU > 10^8/mL) enables consistent Calcium Flux assays (FLIPR) and high-content Internalization imaging with minimal well-to-well variation. |
| Species Translation (Cyno/Mouse) | Ortholog Lentivirus particles for Cynomolgus and Mouse HTR2C available with codon-optimized ORFs for preclinical efficacy bridging studies. |
| False Positives in Cell Assays | Sequence Verified vectors and validated siRNA included for rigorous specificity checks. |
Live HTR2C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The HTR2C therapeutic landscape is undergoing a strategic recalibration following first-generation agonist withdrawals (e.g., Lorcaserin). Current R&D prioritizes bias-selective agonism (favoring Gq signaling over arrestin recruitment) to mitigate tolerance and cardiac safety liabilities associated with HTR2B cross-activation. The convergence of obesity pharmacology with GLP-1 receptor biology has renewed interest in HTR2C as a synergistic target for appetite suppression, driving demand for orthogonal receptor assays that can discriminate subtle conformational pharmacology. Key indications include obesity, Prader-Willi syndrome, epilepsy, and schizophrenia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist (Balanced) | Legacy programs (e.g., Arena, Sanofi) | Obesity, Prader-Willi Syndrome | Calcium Flux (FLIPR) & Internalization assays using high-expression Lentivirus cell lines |
| Biased Agonist (G-protein selective) | Emerging biotech, Academic labs | Obesity (reduced psychiatric side effects) | Arrestin recruitment vs. Calcium bias profiling; requires stable expression systems |
| Allosteric Modulator | Preclinical biotechs | Refractory Obesity, Depression, Addiction | Orthosteric binding competition assays using Membrane Preparations |
| Peptide-Conjugate | Specialized CNS delivery platforms | Hypothalamic targeting | Cell surface accessibility assays (Flow Cytometry) |
| Combo Therapies | Big Pharma | Metabolic Syndrome | Pathway Validation (siRNA specificity controls) |
Molecular Differentiation & Assay Strategy
Subfamily Selectivity
Must absolutely distinguish HTR2C vs HTR2A (psychiatric side effects) vs HTR2B (cardiac valvulopathy). Parallel construction of HTR2A/HTR2B/HTR2C stable cell lines using TarMart homologous lentivirus ensures experimental consistency.
Bias Signaling
Prefer Gq-biased agonists (Calcium release) to avoid arrestin-mediated desensitization. Assays include Calcium Flux (FLIPR), Internalization (high-content imaging), and BRET/Arrestin recruitment.
CNS Penetration
For obesity, balance central (hypothalamus) vs peripheral action; for psychiatry, efficient CNS penetration required. Use TarMart Anti-HTR2C reference antibody for Flow Cytometry to assess cell surface accessibility.
Cross-species Translation
Use TarMart Human/Mouse/Cynomolgus HTR2C ortholog ORF Lentivirus for head-to-head binding affinity and functional potency comparisons in the same cell background.